PCJ Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthQuarterly revenue growth and treatment activity show that ZEVASKYN is progressing from launch toward a commercial operating model. Continued expansion in recognized revenue can improve scale, support market access efforts, and provide a foundation for stronger earnings as treatment volume increases.
Reimbursement ValidationThe NTAP award creates a structural reimbursement pathway for eligible hospital treatments and provides external validation of ZEVASKYN’s clinical improvement. Better reimbursement support may reduce adoption barriers, strengthen provider economics, and help sustain demand as the treatment-center network expands.
Modest LeverageLow leverage gives Abeona more financial flexibility than a heavily indebted biotechnology company while it scales commercialization. The relatively small debt burden can reduce fixed financing pressure and preserve strategic options, although continued losses still require disciplined capital management over time.
Bears Say
Persistent Cash BurnMaterially negative operating and free cash flow means the current business is not yet self-funding. Unless revenue growth and margins improve substantially, ongoing development and commercialization expenses may require external financing, which can reduce financial flexibility and pressure shareholder value.
Manufacturing Yield RiskManufacturing failures directly prevented billing for treatments and forced the company to absorb related costs, showing that production execution can affect both revenue and margins. Repeated yield or specification problems could slow the commercial ramp and undermine confidence in operating consistency.
Treatment-Cadence UncertaintyWide variation between site activation and patient treatment makes near-term volume difficult to forecast, even as the qualified treatment-center network grows. Unpredictable scheduling can delay revenue recognition, complicate capacity planning, and make the commercial ramp more uneven than headline site counts imply.
Abeona Therapeutics News
PCJ FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is CHF207.60M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 23 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Aug 13, 2026. The company reported -CHF0.289 earnings per share for the quarter, missing the consensus estimate of -CHF0.191 by -CHF0.097.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Abeona Therapeutics have?
Currently, no data Available
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -CHF0.289 in its last earnings report, missing expectations of -CHF0.191. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in CH:PCJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF18.06 (― Upside)
CHF18.06 (― Upside)
Blogger Sentiment
Bullish
CH:PCJ Sentiment 92%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth CHF252.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.81%
12-Months-Change
Fundamentals
Return on Equity
-41.69%
Trailing 12-Months
Asset Growth
-27.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
PCJ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights clear commercial progress: 31% quarter-over-quarter revenue growth, expansion to 7 QTCs, 12 patients treated since launch, improved average manufacturing yields in commercial runs, a strong balance sheet ($146.8M) and a significant NTAP reimbursement win that validates the therapy. However, material operational and manufacturing challenges (one low-yield and one out-of-spec batch causing unrevenueed treatments), logistical fragility around the 84-hour shelf life, regulatory work to revisit an assay specification, and continued GAAP losses introduce meaningful near-term execution risk and revenue volatility. Management has implemented clearer reporting metrics and is pursuing operational learnings to mitigate these issues, but variability in site activation and sensitivity to manufacturing yield remain key risks to the revenue ramp.View all CH:PCJ earnings summaries